Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Serum-free Media market Growth is Driven by Technological Advancements & Growing Demand for Cell-Based Therapies AUSTIN, TX, UNITED STATES, November 14, 2024 /EINPresswire / -- According to SNS ...

The fine chemical sector in Europe is witnessing a notable transformation, primarily fueled by the pharmaceutical industry ...

Germany equities were higher at the close on Thursday, as gains in the Technology, Telecoms and Media sectors propelled ...

added 4.64% or 1.37 points to end at 30.76 and Deutsche Telekom AG Na (ETR:DTEGn) was up 3.30% or 0.92 points to 28.77 in ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

The annual inflation rate in Sweden stood at 1.6% in October. On the corporate front, major European companies, including ...

European markets are heading for a mixed open Thursday as traders assessed the global inflation outlook and the possible ...